Background and aim: EBV infection and post-transplant lymphoproliferative disease (PTLD) are closely linked, but the contribution of EBV to graft dysfunction (GD) has not been clearly reported.

[37] PTLD encompasses numerous syndromes associated with EBV-driven lymphoproliferation, whether this is nodal or extranodal, symptomatic or subclinical, localized or disseminated, monoclonal or ...

While these drugs are essential for a successful transplant, they also weaken the immune system, making patients more vulnerable to infections like EBV and increasing the risk of developing PTLD.

Best known for causing mononucleosis, Epstein-Barr virus is also linked to risk for several cancers, including PTLD. More than 90% of adults in the U.S. are or have been infected with EBV.

The cancer – Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV PTLD) – has no approved therapies but is typically treated initially with surgery and radiotherapy ...

Atara had been working with Pierre Fabre Laboratories in a bid to secure approval for Ebvallo in EBV+PTLD for U.S. patients who’ve received at least one prior therapy for their disease.

It can be used in adult and paediatric patients two years of age and older with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD ...